Baxter International Inc. ($BAX) Stock Forecast: Up 5.4% Today

What is Baxter International Inc.?

Baxter International Inc. (BAX) is a global healthcare company that focuses on products to treat hemophilia, kidney disease, immune disorders, and other chronic and acute medical conditions. The company operates in two segments: Americas and International.

Why is Baxter International Inc. going up?

BAX stock is up 5.4% on Apr 30, 2026 19:41

• Despite reporting a Q1 loss, Baxter International Inc. (BAX) experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's ability to surpass Wall Street expectations in terms of adjusted earnings per share and revenue.
• Investors may be optimistic about Baxter's strategic initiatives post the Kidney Care divestiture and the company's reiterated full-year guidance, which could indicate stability and growth potential.
• The positive market response to Baxter's financial results suggests that investors are focusing more on the company's long-term outlook and operational performance rather than short-term losses.

BAX Price Chart

BAX Technical Analysis

BAX News

Baxter International Releases Q1 2026 Financial Results

Baxter International Inc. (BAX) reported stronger-than-expected Q1 2026 results, with adjusted diluted earnings of $0.36 per share, beating the $0.31 consensus. The company posted $2.70B in revenue, a 3.0% increase year-over-year, despite negative organic sales growth from continuing operations. Wall Street analysts maintain a cautious outlook, with most ratings being "hold."

https://news.alphastreet.com/baxter-international-releases-q1-2026-financial-results/

Baxter Posts Q1 Loss Amid Mixed Sales Performance

Baxter International reported a Q1 2026 loss of $17 million, or $0.03 per diluted share, with adjusted EPS down 35% to $0.36, despite worldwide sales of $2.7 billion. Sales grew 3% reported but declined 1% organically, with mixed segment performance and ongoing pressures from higher costs and tariffs. The company reiterated its full-year guidance for flat sales and adjusted EPS of $1.85 to $2.05, focusing on operational stability and strategic initiatives post the Kidney Care divestiture.

https://www.tipranks.com/news/company-announcements/baxter-posts-q1-loss-amid-mixed-sales-performance

Baxter: Q1 Earnings Snapshot

Baxter International Inc. reported a first-quarter loss of $15 million, or 3 cents per share, which is a decline from a profit in the same period last year. Despite the net loss, adjusted earnings of 36 cents per share and revenue of $2.7 billion both surpassed Wall Street expectations. The company anticipates full-year earnings between $1.85 and $2.05 per share.

https://www.kvue.com/article/syndication/associatedpress/baxter-q1-earnings-snapshot/616-40d7ae75-b99e-444e-b29e-4b0bafe0658b

Baxter: Q1 Earnings Snapshot

Baxter International Inc. reported a Q1 loss of $15 million, or 3 cents per share, which adjusted to 36 cents per share, exceeding analyst expectations. The drug and medical device maker also surpassed revenue forecasts with $2.7 billion. Despite the positive earnings surprise, Baxter's shares have dropped 12% year-to-date.

https://www.10tv.com/article/syndication/associatedpress/baxter-q1-earnings-snapshot/616-40d7ae75-b99e-444e-b29e-4b0bafe0658b

Baxter (NYSE: BAX) posts Q1 2026 loss but reiterates 2026 outlook

Baxter International reported a Q1 2026 net loss of $17 million ($0.03 per diluted share) from continuing operations, despite a 3% increase in reported sales to $2.7 billion. Adjusted diluted EPS fell 35% to $0.36, impacted by higher tariffs and manufacturing costs. The company, however, reiterated its full-year 2026 outlook, projecting flat to 1% reported sales growth and adjusted diluted EPS between $1.85 and $2.05, while also declaring a quarterly dividend of $0.01 per share.

https://www.stocktitan.net/sec-filings/BAX/8-k-baxter-international-inc-reports-material-event-6d6b4336d1d8.html

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.9% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 15.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 7.5% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 6.0% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 23.2% Today

Upstart Holdings Inc. ($UPST) Stock Forecast: Down 9.5% Today

Internationa Flavors & Fragrances Inc. ($IFF) Stock Forecast: Up 17.2% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 6.0% Today

Devon Energy Corporation ($DVN) Stock Forecast: Down 8.6% Today

Taiwan Semiconductor Manufacturing Company Ltd. ($TSM) Stock Forecast: Up 6.3% Today

Baxter International Inc. Price History

19.02.2026 - BAX Stock was down 5.7%

• Baxter International (BAX) recently saw a decline in its stock price following the departure of its CFO, Joel Grade, amid ongoing governance reviews and product safety investigations.
• Concerns over the CFO transition and governance matters have led to uncertainties about the company's financial strategy and cost management in the eyes of investors.
• The questioning of Axogen's (AXGN) valuation and the growth of the regenerative medicine sector could have also played a part in affecting investor confidence in Baxter International, contributing to the downward trend.
• It is recommended for investors to observe how Baxter International communicates its financial strategies and handles risks during these changes to evaluate the potential impact on its stock performance.

01.03.2026 - BAX Stock was up 5.1%

• The bullish movement in Baxter International Inc. (BAX) stock can be attributed to the launch of its IV Verify Line Labeling System, showcasing the company's commitment to improving patient safety and nurse productivity in clinical settings.
• The positive market response indicates investor confidence in Baxter's strategic developments and potential for revenue growth in the global intravenous solutions market.
• Despite some recent declines in stock performance, this innovative product launch has reignited investor interest and positioned Baxter International for further market expansion and success in the healthcare industry.

30.03.2026 - BAX Stock was up 5.4%

• Despite reporting a Q1 loss, Baxter International Inc. (BAX) experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's ability to surpass Wall Street expectations in terms of adjusted earnings per share and revenue.
• Investors may be optimistic about Baxter's strategic initiatives post the Kidney Care divestiture and the company's reiterated full-year guidance, which could indicate stability and growth potential.
• The positive market response to Baxter's financial results suggests that investors are focusing more on the company's long-term outlook and operational performance rather than short-term losses.

30.03.2026 - BAX Stock was up 3.2%

• Despite posting a Q1 loss, Baxter International Inc. experienced a strong bullish movement in the stock market.
• The bullish trend could be attributed to the company's robust sales performance, with revenue exceeding expectations and demonstrating a 5% year-over-year increase.
• Investors may have been encouraged by Baxter's resilience in the face of challenges like higher costs and tariffs, as well as the company's reaffirmation of its full-year guidance and strategic initiatives.
• The market reaction, with the stock soaring 7.6%, indicates investor confidence in Baxter's ability to navigate the medtech market landscape and drive long-term growth.

26.02.2026 - BAX Stock was up 5.1%

• BAX stock rose by 2.39% to $17.12, surpassing its competitors for the third consecutive day.
• The positive market sentiment, reflected in the S&P 500 Index and Dow Jones Industrial Average increases, likely contributed to this rise.
• Investor optimism about Baxter's product portfolio and growth opportunities, especially in healthcare, may have fuelled its strong performance.
• Although therapy animal program news is beneficial for healthcare, it had minimal direct impact on BAX's stock movement.

27.02.2026 - BAX Stock was down 5.2%

• Baxter International Inc. (BAX) experienced a substantial 2.63% drop to $16.67, halting a previous positive trend in concurrence with the broader bearish market conditions.
• Following a downgrade in the outlook by S&P, citing concerns about leverage and free cash flow, Bank of America maintained a Hold rating on BAX.
• Investor interest heightened due to a recent CFO change at Baxter International, with the stock trading below its estimated fair value, hinting at potential undervaluation.
• Despite The Vanguard Group reporting 0% ownership post an internal rearrangement, which had no substantial impact on the stock's performance, as it was merely an administrative adjustment.

27.02.2026 - BAX Stock was down 6.4%

• Bank of America maintained a Hold rating on Baxter International (BAX) with a $24 price target, while S&P downgraded the stock's outlook to Negative, causing a bearish movement.
• The recent CFO transition at Baxter International (BAX) has raised concerns about its valuation, as the stock is trading below the fair value, suggesting potential undervaluation.
• Baxter International Inc. (BAX) stock performed poorly compared to its competitors on a negative trading day, contributing to the overall bearish trend.
• Despite the announcement of Baxter's online-only annual meeting and the focus on convenience and cost-effectiveness, it did not prevent the decline in the stock amidst negative market sentiment.

14.03.2026 - BAX Stock was up 5.6%

• Baxter International Inc. showcased its latest innovations, including the AAT XR spine surgical table and Dynamo Series smart stretcher, at the AORN Global Surgical Conference & Expo. These new products aim to improve efficiency, support safer patient care, and address common challenges faced by healthcare teams in surgical settings.
• The company's stock outperformed competitors on a strong trading day, rising by 2.80%. This positive market reaction could be attributed to investor optimism surrounding Baxter's commitment to evolving its portfolio through collaboration with healthcare professionals and its focus on enhancing efficiency and patient care.
• The emphasis on Baxter's new surgical and patient support products, designed to enhance efficiency, streamline workflows, and improve patient care in operating rooms, likely contributed to the bullish movement in the stock price.
• Overall, the market responded positively to Baxter's innovative product showcase at the conference, reflecting investor confidence in the company's ability to drive growth and address the evolving needs of the healthcare industry.

29.03.2026 - BAX Stock was down 5.6%

• Baxter International Inc. (BAX) stock declined by 2.97% on Tuesday, performing below market indices.
• Analysts predict stagnant year-on-year revenue for Q1 earnings, indicating a slowdown compared to previous periods.
• Challenges in product categories aimed at hospitals and unfavorable comparisons are expected to have a negative impact on revenue.
• BlackRock Inc.'s 6.4% ownership filing in Baxter International Inc. may have affected market sentiment, contributing to the bearish trend.

29.03.2026 - BAX Stock was down 5.3%

• Baxter International Inc. (BAX) stock experienced a strong bearish movement, falling 2.97% to $17.94, underperforming the market indices.
• The stock's underperformance could be attributed to the broader market decline, as both the S&P 500 Index and Dow Jones Industrial Average also saw decreases.
• Despite the company's positive Q1 earnings report and potential for recovery, the market pressures and the stock closing significantly below its 52-week high might have contributed to the bearish movement.
• The filing by BlackRock Inc. showing a 6.4% ownership of Baxter International Inc. shares could also be a factor influencing market sentiment, although not directly causing the bearish movement.

31.02.2026 - BAX Stock was up 5.0%

• Baxter International experienced a bullish movement following the successful launch of its IV Verify Line Labeling System, designed to enhance IV medication accuracy and minimize errors in clinical environments.
• Market response has been positive towards Baxter's efforts to reinforce its infusion therapy ecosystem, as demonstrated by its partnership with Vigilant Software to address compliance issues and streamline nurse operations.
• Despite recent stock declines, investor outlook appears bullish on Baxter's ability to leverage the growing intravenous solutions market with this new technology, contributing to today's positive performance.
• The introduction of this cutting-edge system underscores Baxter's dedication to innovation and patient safety, potentially increasing investor trust and driving the stock's upward momentum amid a day of mixed trading in the broader market.

17.03.2026 - BAX Stock was up 8.2%

• Baxter International Inc. stock witnessed a notable surge today, possibly due to its defensive growth profile and focus on essential hospital products.
• The company's strong position in the healthcare sector, emphasizing its hospital supply advantage, could have attracted investors seeking stability in uncertain economic times.
• With the increasing demand for crucial medical supplies, Baxter International Inc.'s stock performance may be benefiting from the rising need for its products, particularly in the expanding Blood And Blood Components Market.
• The generally positive market outlook towards healthcare stocks, alongside Baxter International Inc.'s robust business model and market positioning, likely played a role in its bullish movement today.